Skip to main content
Top
Published in: World Journal of Surgical Oncology 1/2014

Open Access 01-12-2014 | Research

Elevated serum CA19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: a pilot study

Authors: Qian Dong, Xiang-hong Yang, Yao Zhang, Wei Jing, Li-qiang Zheng, Yun-peng Liu, Xiu-juan Qu

Published in: World Journal of Surgical Oncology | Issue 1/2014

Login to get access

Abstract

Background

Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive human cancers. Several studies have reported that the carbohydrate antigen 19-9 (CA19-9) level is a useful marker for predicting the prognosis for PDAC after resection. However, the cutoff value of CA19-9 used to predict prognosis varied among these reports. The aims of this study were to evaluate whether the serum CA19-9 level is a significant predictor for survival and to determine the optimal cutoff value of CA19-9 for predicting prognosis.

Methods

A total of 120 consecutive patients who underwent surgery for potentially resectable primary PDAC were retrospectively analyzed. The variables included the following: age, sex, the location of the tumor, the maximal tumor size, the histological differentiation, the margin status, the tumor stage, serum CA19-9 levels, and serum total bilirubin (TBil) levels.

Results

The overall 1-year survival rate was 62.5%. The receiver operating characteristic (ROC) curve indicated a significant result for the level of CA19-9 in predicting death within 1 year after surgery (Area under the curve (AUC), 0.612; 95% confidence interval (CI), 0.505-0.720; P = 0.040). The optimal cutoff point was 338.45 U/mL (sensitivity, 60.0%; specificity, 66.7%; accuracy, 64.2%). The strongest univariate predictor among the categorized CA19-9 values was CA19-9 greater than or equal to 338.45 U/mL. In the multivariate Cox proportional hazards mode analysis, the serum CA19-9 level, age and the histological differentiation were significant independent prognostic factors that were associated with the overall survival.

Conclusions

The preoperative elevated CA19-9 level is a promising independent factor for predicting a poor prognosis in PDAC, and the optimal cutoff value is 338.45 U/mL.
Appendix
Available only for authorised users
Literature
1.
go back to reference Luo J, Xiao L, Wu C, Zheng Y, Zhao N: The incidence and survival rate of population-based pancreatic cancer patients:shanghai cancer registry 2004-2009. PLoS One. 2013, 8: e76052-10.1371/journal.pone.0076052.PubMedCentralCrossRefPubMed Luo J, Xiao L, Wu C, Zheng Y, Zhao N: The incidence and survival rate of population-based pancreatic cancer patients:shanghai cancer registry 2004-2009. PLoS One. 2013, 8: e76052-10.1371/journal.pone.0076052.PubMedCentralCrossRefPubMed
2.
go back to reference Pannala R, Basu A, Petersen GM, Chari ST: New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer. Lancet Oncol. 2009, 10: 88-95. 10.1016/S1470-2045(08)70337-1.PubMedCentralCrossRefPubMed Pannala R, Basu A, Petersen GM, Chari ST: New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer. Lancet Oncol. 2009, 10: 88-95. 10.1016/S1470-2045(08)70337-1.PubMedCentralCrossRefPubMed
3.
go back to reference Barugola G, Partelli S, Marcucci S, Sartori N, Capelli P, Bassi C, Pederzoli P, Falconi M: Resectable pancreatic cancer: who really benefits from resection?. Ann Surg Oncol. 2009, 16: 3316-3322. 10.1245/s10434-009-0670-7.CrossRefPubMed Barugola G, Partelli S, Marcucci S, Sartori N, Capelli P, Bassi C, Pederzoli P, Falconi M: Resectable pancreatic cancer: who really benefits from resection?. Ann Surg Oncol. 2009, 16: 3316-3322. 10.1245/s10434-009-0670-7.CrossRefPubMed
4.
go back to reference De La Cruz MS, Young AP, Ruffin MT: Diagnosis and management of pancreatic cancer. Am Fam Physician. 2014, 89: 626-632.PubMed De La Cruz MS, Young AP, Ruffin MT: Diagnosis and management of pancreatic cancer. Am Fam Physician. 2014, 89: 626-632.PubMed
5.
go back to reference Kobayashi M, Mizuno S, Murata Y, Kishiwada M, Usui M, Sakurai H, Tabata M, Ii N, Yamakado K, Inoue H, Shiraishi T, Yamada T, Isaji S: Gemcitabine-based chemoradiotherapy followed by surgery for borderline resectable and locally unresectablepancreatic ductal adenocarcinoma: significance of the CA19-9 reduction rate and intratumoral human equilibrative nucleoside transporter 1 expression. Pancreas. 2014, 43: 350-360. 10.1097/MPA.0000000000000059.PubMedCentralCrossRefPubMed Kobayashi M, Mizuno S, Murata Y, Kishiwada M, Usui M, Sakurai H, Tabata M, Ii N, Yamakado K, Inoue H, Shiraishi T, Yamada T, Isaji S: Gemcitabine-based chemoradiotherapy followed by surgery for borderline resectable and locally unresectablepancreatic ductal adenocarcinoma: significance of the CA19-9 reduction rate and intratumoral human equilibrative nucleoside transporter 1 expression. Pancreas. 2014, 43: 350-360. 10.1097/MPA.0000000000000059.PubMedCentralCrossRefPubMed
6.
go back to reference Tempero MA, Uchida E, Takasaki H, Burnett DA, Steplewski Z, Pour PM: Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer. Cancer Res. 1987, 47: 5501-5503.PubMed Tempero MA, Uchida E, Takasaki H, Burnett DA, Steplewski Z, Pour PM: Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer. Cancer Res. 1987, 47: 5501-5503.PubMed
7.
go back to reference Berger AC, Meszoely IM, Ross EA, Watson JC, Hoffman JP: Undetectable preoperative levels of serum CA 19-9 correlate with improved survival for patients with resectable pancreatic adenocarcinoma. Ann Surg Oncol. 2004, 11: 644-649. 10.1245/ASO.2004.11.025.CrossRefPubMed Berger AC, Meszoely IM, Ross EA, Watson JC, Hoffman JP: Undetectable preoperative levels of serum CA 19-9 correlate with improved survival for patients with resectable pancreatic adenocarcinoma. Ann Surg Oncol. 2004, 11: 644-649. 10.1245/ASO.2004.11.025.CrossRefPubMed
8.
go back to reference Distler M, Pilarsky E, Kersting S, Grützmann R: Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study. Int J Surg. 2013, 11: 1067-1072. 10.1016/j.ijsu.2013.10.005.CrossRefPubMed Distler M, Pilarsky E, Kersting S, Grützmann R: Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study. Int J Surg. 2013, 11: 1067-1072. 10.1016/j.ijsu.2013.10.005.CrossRefPubMed
9.
go back to reference Mehta J, Prabhu R, Eshpuniyani P, Kantharia C, Supe A: Evaluating the efficacy of tumor markers CA 19-9 and CEA to predict operability and survival in pancreatic malignancies. Trop Gastroenterol. 2010, 31: 190-194.PubMed Mehta J, Prabhu R, Eshpuniyani P, Kantharia C, Supe A: Evaluating the efficacy of tumor markers CA 19-9 and CEA to predict operability and survival in pancreatic malignancies. Trop Gastroenterol. 2010, 31: 190-194.PubMed
10.
go back to reference Waraya M, Yamashita K, Katagiri H, Ishii K, Takahashi Y, Furuta K, Watanabe M: Preoperative serum CA19-9 and dissected peripancreatic tissue margin as determiners of long-term survival in pancreatic cancer. Ann Surg Oncol. 2009, 16: 1231-1240. 10.1245/s10434-009-0415-7.CrossRefPubMed Waraya M, Yamashita K, Katagiri H, Ishii K, Takahashi Y, Furuta K, Watanabe M: Preoperative serum CA19-9 and dissected peripancreatic tissue margin as determiners of long-term survival in pancreatic cancer. Ann Surg Oncol. 2009, 16: 1231-1240. 10.1245/s10434-009-0415-7.CrossRefPubMed
11.
go back to reference Sugiura T, Uesaka K, Kanemoto H, Mizuno T, Sasaki K, Furukawa H, Matsunaga K, Maeda A: Serum CA19-9 is significant predictor among preoperative parameters for early recurrence after resection of pancreatic adenocarcinoma. J Gastrointest Surg. 2012, 16: 977-985. 10.1007/s11605-012-1859-9.CrossRefPubMed Sugiura T, Uesaka K, Kanemoto H, Mizuno T, Sasaki K, Furukawa H, Matsunaga K, Maeda A: Serum CA19-9 is significant predictor among preoperative parameters for early recurrence after resection of pancreatic adenocarcinoma. J Gastrointest Surg. 2012, 16: 977-985. 10.1007/s11605-012-1859-9.CrossRefPubMed
12.
go back to reference Ueda M, Endo I, Nakashima M, Minami Y, Takeda K, Matsuo K, Nagano Y, Tanaka K, Ichikawa Y, Togo S, Kunisaki C, Shimada H: Prognostic factors after resection of pancreatic cancer. World J Surg. 2009, 33: 104-110. 10.1007/s00268-008-9807-2.CrossRefPubMed Ueda M, Endo I, Nakashima M, Minami Y, Takeda K, Matsuo K, Nagano Y, Tanaka K, Ichikawa Y, Togo S, Kunisaki C, Shimada H: Prognostic factors after resection of pancreatic cancer. World J Surg. 2009, 33: 104-110. 10.1007/s00268-008-9807-2.CrossRefPubMed
13.
go back to reference Barton JG, Bois JP, Sarr MG, Wood CM, Qin R, Thomsen KM, Kendrick ML, Farnell MB: Predictive and prognostic value of CA19-9 in resected pancreatic adenocarcinoma. J Gastrointest Surg. 2009, 13: 2050-2058. 10.1007/s11605-009-0849-z.CrossRefPubMed Barton JG, Bois JP, Sarr MG, Wood CM, Qin R, Thomsen KM, Kendrick ML, Farnell MB: Predictive and prognostic value of CA19-9 in resected pancreatic adenocarcinoma. J Gastrointest Surg. 2009, 13: 2050-2058. 10.1007/s11605-009-0849-z.CrossRefPubMed
14.
go back to reference Hartwig W, Strobel O, Hinz U, Fritz S, Hackert T, Roth C, Büchler MW, Werner J: CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy. Ann Surg Oncol. 2013, 20: 2188-2196. 10.1245/s10434-012-2809-1.CrossRefPubMed Hartwig W, Strobel O, Hinz U, Fritz S, Hackert T, Roth C, Büchler MW, Werner J: CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy. Ann Surg Oncol. 2013, 20: 2188-2196. 10.1245/s10434-012-2809-1.CrossRefPubMed
15.
go back to reference Hirakawa T, Nakata B, Amano R, Kimura K, Shimizu S, Ohira G, Yamada N, Ohira M, Hirakawa K: HER3 overexpression as an independent indicator of poor prognosis for patients with curatively resected pancreatic cancer. Oncology. 2011, 81: 192-198. 10.1159/000333825.CrossRefPubMed Hirakawa T, Nakata B, Amano R, Kimura K, Shimizu S, Ohira G, Yamada N, Ohira M, Hirakawa K: HER3 overexpression as an independent indicator of poor prognosis for patients with curatively resected pancreatic cancer. Oncology. 2011, 81: 192-198. 10.1159/000333825.CrossRefPubMed
16.
go back to reference Haglund C, Roberts PJ, Kuusela P, Scheinin TM, Mäkelä O, Jalanko H: Evaluation of CA 19-9 as a serum tumour marker in pancreatic cancer. Br J Cancer. 1986, 53: 197-202. 10.1038/bjc.1986.35.PubMedCentralCrossRefPubMed Haglund C, Roberts PJ, Kuusela P, Scheinin TM, Mäkelä O, Jalanko H: Evaluation of CA 19-9 as a serum tumour marker in pancreatic cancer. Br J Cancer. 1986, 53: 197-202. 10.1038/bjc.1986.35.PubMedCentralCrossRefPubMed
17.
go back to reference Edge SB, Byrd DR, Compton CC: AJCC cancer staging manual. 2010, New York: Springer Edge SB, Byrd DR, Compton CC: AJCC cancer staging manual. 2010, New York: Springer
18.
go back to reference Schlieman MG, Ho HS, Bold RJ: Utility of tumor markers in determining respectability of pancreatic cancer. Arch Surg. 2003, 138: 951-955. 10.1001/archsurg.138.9.951.CrossRefPubMed Schlieman MG, Ho HS, Bold RJ: Utility of tumor markers in determining respectability of pancreatic cancer. Arch Surg. 2003, 138: 951-955. 10.1001/archsurg.138.9.951.CrossRefPubMed
19.
go back to reference Kondo N, Murakami Y, Uemura K, Hayashidani Y, Sudo T, Hashimoto Y, Nakashima A, Sakabe R, Shigemoto N, Kato Y, Ohge H, Sueda T: Prognostic impact of perioperative serum CA 19-9 levels in patients with resectable pancreatic cancer. Ann Surg Oncol. 2010, 17: 2321-2329. 10.1245/s10434-010-1033-0.CrossRefPubMed Kondo N, Murakami Y, Uemura K, Hayashidani Y, Sudo T, Hashimoto Y, Nakashima A, Sakabe R, Shigemoto N, Kato Y, Ohge H, Sueda T: Prognostic impact of perioperative serum CA 19-9 levels in patients with resectable pancreatic cancer. Ann Surg Oncol. 2010, 17: 2321-2329. 10.1245/s10434-010-1033-0.CrossRefPubMed
20.
go back to reference Ferrone CR, Finkelstein DM, Thayer SP, Muzikansky A, Fernandez-delCastillo C, Warshaw AL: Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol. 2006, 24: 2897-2902. 10.1200/JCO.2005.05.3934.CrossRefPubMed Ferrone CR, Finkelstein DM, Thayer SP, Muzikansky A, Fernandez-delCastillo C, Warshaw AL: Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol. 2006, 24: 2897-2902. 10.1200/JCO.2005.05.3934.CrossRefPubMed
21.
go back to reference Goonetilleke KS, Siriwardena AK: Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol. 2007, 33: 266-270. 10.1016/j.ejso.2006.10.004.CrossRefPubMed Goonetilleke KS, Siriwardena AK: Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol. 2007, 33: 266-270. 10.1016/j.ejso.2006.10.004.CrossRefPubMed
22.
go back to reference Hartwig W, Hackert T, Hinz U, Gluth A, Bergmann F, Strobel O, Büchler MW, Werner J: Pancreatic cancer surgery in the new millennium: better prediction of outcome. Ann Surg. 2011, 254: 311-319. 10.1097/SLA.0b013e31821fd334.CrossRefPubMed Hartwig W, Hackert T, Hinz U, Gluth A, Bergmann F, Strobel O, Büchler MW, Werner J: Pancreatic cancer surgery in the new millennium: better prediction of outcome. Ann Surg. 2011, 254: 311-319. 10.1097/SLA.0b013e31821fd334.CrossRefPubMed
23.
go back to reference Kang CM, Kim JY, Choi GH, Kim KS, Choi JS, Lee WJ, Kim BR: The use of adjusted preoperative CA 19-9 to predict the recurrence of resectable pancreatic cancer. J Surg Res. 2007, 140: 31-35. 10.1016/j.jss.2006.10.007.CrossRefPubMed Kang CM, Kim JY, Choi GH, Kim KS, Choi JS, Lee WJ, Kim BR: The use of adjusted preoperative CA 19-9 to predict the recurrence of resectable pancreatic cancer. J Surg Res. 2007, 140: 31-35. 10.1016/j.jss.2006.10.007.CrossRefPubMed
24.
go back to reference Kalthoff H, Kreiker C, Schmiegel WH, Greten H, Thiele HG: Characterization of CA19-9 bearing mucins as physiological exocrine pancreatic secretion products. Cancer Res. 1986, 46: 3605-3607.PubMed Kalthoff H, Kreiker C, Schmiegel WH, Greten H, Thiele HG: Characterization of CA19-9 bearing mucins as physiological exocrine pancreatic secretion products. Cancer Res. 1986, 46: 3605-3607.PubMed
25.
go back to reference Rahbari NN, Bork U, Hinz U, Leo A, Kirchberg J, Koch M, Büchler MW, Weitz J: AB0 blood group and prognosis in patients with pancreatic cancer. BMC Cancer. 2012, 12: 319-10.1186/1471-2407-12-319.PubMedCentralCrossRefPubMed Rahbari NN, Bork U, Hinz U, Leo A, Kirchberg J, Koch M, Büchler MW, Weitz J: AB0 blood group and prognosis in patients with pancreatic cancer. BMC Cancer. 2012, 12: 319-10.1186/1471-2407-12-319.PubMedCentralCrossRefPubMed
26.
go back to reference Berger AC, Garcia M, Hoffman JP, Regine WF, Abrams RA, Safran H, Konski A, Benson AB, MacDonald J, Willett CG: Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704. J Clin Oncol. 2008, 26: 5918-5922. 10.1200/JCO.2008.18.6288.PubMedCentralCrossRefPubMed Berger AC, Garcia M, Hoffman JP, Regine WF, Abrams RA, Safran H, Konski A, Benson AB, MacDonald J, Willett CG: Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704. J Clin Oncol. 2008, 26: 5918-5922. 10.1200/JCO.2008.18.6288.PubMedCentralCrossRefPubMed
27.
go back to reference Kinsella TJ, Seo Y, Willis J, Stellato TA, Siegel CT, Harpp D, Willson JK, Gibbons J, Sanabria JR, Hardacre JM, Schulak JP: The impact of resection margin status and postoperative CA19-9 levels on survival and patterns of recurrence after postoperative high-dose radiotherapy with 5-FU-based concurrent chemotherapy for resectable pancreatic cancer. Am J Clin Oncol. 2008, 31: 446-453. 10.1097/COC.0b013e318168f6c4.CrossRefPubMed Kinsella TJ, Seo Y, Willis J, Stellato TA, Siegel CT, Harpp D, Willson JK, Gibbons J, Sanabria JR, Hardacre JM, Schulak JP: The impact of resection margin status and postoperative CA19-9 levels on survival and patterns of recurrence after postoperative high-dose radiotherapy with 5-FU-based concurrent chemotherapy for resectable pancreatic cancer. Am J Clin Oncol. 2008, 31: 446-453. 10.1097/COC.0b013e318168f6c4.CrossRefPubMed
28.
go back to reference Chang DK, Johns AL, Merrett ND, Gill AJ, Colvin EK, Scarlett CJ, Nguyen NQ, Leong RW, Cosman PH, Kelly MI, Sutherland RL, Henshall SM, Kench JG, Biankin AV: Margin clearance and outcome in resected pancreatic cancer. J Clin Oncol. 2009, 27: 2855-2862. 10.1200/JCO.2008.20.5104.CrossRefPubMed Chang DK, Johns AL, Merrett ND, Gill AJ, Colvin EK, Scarlett CJ, Nguyen NQ, Leong RW, Cosman PH, Kelly MI, Sutherland RL, Henshall SM, Kench JG, Biankin AV: Margin clearance and outcome in resected pancreatic cancer. J Clin Oncol. 2009, 27: 2855-2862. 10.1200/JCO.2008.20.5104.CrossRefPubMed
29.
go back to reference Kim J, Reber HA, Dry SM, Elashoff D, Chen SL, Umetani N, Kitago M, Hines OJ, Kazanjian KK, Hiramatsu S, Bilchik AJ, Yong S, Shoup M, Hoon DS: Unfavourable prognosis associated with K-ras gene mutation in pancreatic cancer surgical margins. Gut. 2006, 55: 1598-1605. 10.1136/gut.2005.083063.PubMedCentralCrossRefPubMed Kim J, Reber HA, Dry SM, Elashoff D, Chen SL, Umetani N, Kitago M, Hines OJ, Kazanjian KK, Hiramatsu S, Bilchik AJ, Yong S, Shoup M, Hoon DS: Unfavourable prognosis associated with K-ras gene mutation in pancreatic cancer surgical margins. Gut. 2006, 55: 1598-1605. 10.1136/gut.2005.083063.PubMedCentralCrossRefPubMed
30.
go back to reference Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 2012, 62: 10-29. 10.3322/caac.20138.CrossRefPubMed Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 2012, 62: 10-29. 10.3322/caac.20138.CrossRefPubMed
Metadata
Title
Elevated serum CA19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: a pilot study
Authors
Qian Dong
Xiang-hong Yang
Yao Zhang
Wei Jing
Li-qiang Zheng
Yun-peng Liu
Xiu-juan Qu
Publication date
01-12-2014
Publisher
BioMed Central
Published in
World Journal of Surgical Oncology / Issue 1/2014
Electronic ISSN: 1477-7819
DOI
https://doi.org/10.1186/1477-7819-12-171

Other articles of this Issue 1/2014

World Journal of Surgical Oncology 1/2014 Go to the issue